Compugen Q3 Loss Narrower Than Expected; Revenue More Than Doubles
CGEN sits 39% above its 52-week low of $1.43 on light trading volume (0.1× avg).
Summary
Compugen posted a Q3 adjusted loss of 6 cents a share, better than the 8-cent loss five analysts expected, and revenue of $3.82 million versus a $1.70 million consensus — up 102.1% from a year ago. The quarter's net loss was $5.8 million. The company ended with $117.5 million in cash, which it says funds operations into 2029, so there is no near-term financing pressure despite the ongoing losses. The stock is down 17.6% this quarter but up 28.1% year to date, and the average analyst rating is 'strong buy' with a median 12-month price target of $4.00 versus a $1.96 last close. The revenue beat against a small consensus base is the number that matters here — it shows the collaboration revenue line is running ahead of expectations.
At the time of this announcement, CGEN was trading at $1.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188.5M. The 52-week trading range was $1.43 to $3.24. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.